Danoprevir
- Generic Name
- Danoprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C35H46FN5O9S
- CAS Number
- 850876-88-9
- Unique Ingredient Identifier
- 911Z9PCQ5F
- Background
Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
- Indication
本品应与利托那韦、聚乙二醇干扰素α和利巴韦林联合组成抗病毒治疗方案，用于治疗初治的非肝硬化的基因1b型慢性丙型肝炎成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT01592318
A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01588002
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01579019
A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01531647
A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01519336
A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01514968
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT01483742
A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT01483729
A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01418274
A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01398293
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath